You are here » Home » Companies » Company Overview » Sanofi India Ltd

Sanofi India Ltd.

BSE: 500674 Sector: Health care
NSE: SANOFI ISIN Code: INE058A01010
BSE 00:00 | 18 Oct 6100.40 45.10
(0.74%)
OPEN

6120.00

HIGH

6275.00

LOW

5925.00

NSE 00:00 | 18 Oct 5996.25 -56.55
(-0.93%)
OPEN

6300.00

HIGH

6300.00

LOW

5920.15

OPEN 6120.00
PREVIOUS CLOSE 6055.30
VOLUME 10121
52-Week high 6584.00
52-Week low 5300.00
P/E 36.14
Mkt Cap.(Rs cr) 14,049
Buy Price 5939.00
Buy Qty 2.00
Sell Price 5988.00
Sell Qty 2.00
OPEN 6120.00
CLOSE 6055.30
VOLUME 10121
52-Week high 6584.00
52-Week low 5300.00
P/E 36.14
Mkt Cap.(Rs cr) 14,049
Buy Price 5939.00
Buy Qty 2.00
Sell Price 5988.00
Sell Qty 2.00

Sanofi India Ltd. (SANOFI) - Chairman Speech

Company chairman speech

RAJARAM NARAYANAN

Dear Shareholders

At the outset I wish to thank all of you for the trust and confidence you have placedin the Company. With your support your Company continues to excel in providing worldclass innovative accessible medicines to millions of patients in the country and aroundthe world.

In recent months healthcare has received special attention in India. With AyushmanBharat India has taken a major leap towards providing universal healthcare. As thisprogram reaches the implementation stage we hope to see several public-privatepartnerships which will result in better access to affordable quality healthcaresolutions to all Indians.

India continues to be amongst the fastest growing pharmaceutical markets in the worldwith an operating environment that is dynamic and full of surprises. The industry hasfaced several headwinds including the effects of the Goods & Services Tax (GST) banson certain fixed dose combinations and challenges on the policy front. Your Company hasnavigated this challenging environment commendably through agile initiatives andexcellence in execution while keeping patients at the centre of all its activities.

You will be proud that your Company had yet another year of strong performancedelivering double-digit revenue growth in the year under review. In 2018 we introducednew innovative medicines that strengthened our presence in key therapy areas. We continuedto increase awareness and availability of our strong diversified portfolio in diabetescardiology central nervous system diseases thrombosis respiratory and anti- infectives.Our robust manufacturing footprint provided strong support to our ambition as our sitesdelivered world class medicines for domestic and international markets. tThe exportsoperations hold a special place in your Company delivering quality healthcare solutionsto over 50 international markets. India is destined to be a leading centre for drugmanufacturing and your Company is well placed to play an important role in this journey.

Technology has become a key disruptor and differentiator in healthcare. Your Companyhas introduced several digital initiatives to reach more patients and doctors creatingawareness of diseases and enhancing capability of healthcare practitioners. Our pioneeringpatient support programs leverage digital technology for delivering better healthoutcomes. Your Company is also rapidly digitising all commercial and manufacturingoperations receiving strong support from Sanofi's global expertise.

As a health journey partner our purpose is Empowering Life bringing value tosociety by protecting enabling and supporting people facing health challenges through ourdrug treatments and healthcare initiatives. Your Company firmly believes in making apositive contribution to our communities and giving back to society. I am proud that in2018 your company expanded its commitment to Corporate Social Responsibility (CSR) throughvarious programs in awareness education and employee volunteering some of which havebeen developed and executed in partnership with the State and Central Government. YourCompany places the highest emphasis on safety and responsible ethical practices. Ouremployees and partners are continuously engaged in living the values of Sanofi througheducation training and strong governance.

Our employees remain our pride - with their dedication and commitment to make adifference to millions of patients. Our global employee surveys have revealedexceptionally high engagement scores with a majority of our employees extremely proud towork with Sanofi. We continue to accord the highest importance to employee welfare andimplement progressive practices like flexible working hours for our people. Your Companyhas put in place a transformational roadmap for human resources. We are committed tobuilding a future-ready organisation driven by purpose and attractive to millennials andthe talent of the future. The Company places highest priority on promoting diversityinclusiveness and gender balance.

Today we are living in exciting times. While there are uncertainties your Company hasalways adapted to rise to the challenges and seize the opportunities. With the support ofour partners and stakeholders we will continue to work passionately every day tounderstand and solve the healthcare needs of people. India holds a special place for theSanofi group and we are privileged to receive their global expertise and support at everystage.

Once again I take this opportunity to thank every shareholder for your support at alltimes in the progress and development of your Company.

I also express my gratitude to the employees of the Company for their unwaveringcommitment to the values of Sanofi and for their relentless perseverance to make surethat every person gets the gift of good health.

My best wishes to you and your families for a happy and healthy 2019.

Yours sincerely

Rajaram Narayanan.

Chairman